Intra-arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an IAEA-sponsored Multination Study.
Patricia Bernal,Jean-Luc Raoul,Gaj Vidmar,Erdenechimeg Sereegotov,Felix X. Sundram,Ajay Kumar,Jae Min Jeong,Pawana Pusuwan,Chaitanya Divgi,Pat Zanzonico,Janez Stare,John Buscombe,Chau Trinh Thi Minh,Maung,Shaoliang Chen,Ruben Ogbac,Ajit K. Padhy
DOI: https://doi.org/10.1016/j.ijrobp.2007.05.009
2007-01-01
Abstract:Purpose: Intra-arterial injections (IAI) of 1311-lipiodol is effective in treating hepatocellular carcinoma patients, but is expensive and requires a 7-day hospitalization in a radioprotection room. 188Re is inexpensive, requires no patient isolation, and can be used with lipiodol.Methods and Materials: This International Atomic Energy Agency-sponsored phase II trial aimed to assess the safety and the efficacy of a radioconjugate 188Re + lipiodol (188Re-Lip) in a large cohort of hepatocellular carcinoma patients from developing countries. A scout dose is used to determine the maximal tolerated dose (lungs < 12 Gy, normal liver < 30 Gy, bone marrow < 1.5 Gy) and then the delivery of the calculated activity. Efficacy was assessed using response evaluation criteria in solid tumor (RECIST) and alpha-feto-protein (alpha FP) levels and severe adverse events were graded using the Common Toxicity Criteria of the National Cancer Institute scale v2.0.Results: The trial included 185 patients from eight countries. The procedure was feasible in all participating centers. One treatment was given to 134 patients; 42, 8, and 1 received two, three, and four injections, respectively. The injected activity during the first treatment was 100 mCi. Tolerance was excellent. We observed three complete responses and 19 partial responses (22% of evaluable patients, 95% confidence interval 16-35%); 1- and 2-year survivals were 46% and 23%. Some factors affected survival: country of origin, existence of a cirrhosis, Cancer of the Liver Italian Program score, tumor dose, absence of progression, and posttreatment decrease in aFP level.Conclusions: IAI of 188Re-Lip in developing countries is feasible, safe, cost-effective, and deserves a phase III trial. (c) 2007 Elsevier Inc.